Muscles need dystrophin in order to regenerate. Persons suffering from Duchenne muscular dystrophy lack this essential muscular protein due to mutations in the gene which is responsible for producing dystrophin. As a result, their existing muscle cells deteriorate over time and are gradually replaced by connective and fatty tissue; muscle strength weakens during the course of the disease. The first symptoms usually appear around the age of five. Children with the disease begin to have difficulties with movements they previously completed with ease, for example climbing stairs or getting up from the floor. At approximately the age of twelve, they are no longer able to walk, later losing movement in their arms and hands. Due to concomitant respiratory and cardiac failure, the majority of patients does not reach the age of 40. DMD affects mainly boys, since the responsible mutations are located in the dystrophin gene on the X chromosome.
Gene scissors remove defective gene sequence
An interdisciplinary Munich research team led by scientists from TUM has for the first time succeeded in correcting the mutated dystrophin gene in living pigs. In order to cut the defective gene sequence from the DNA of the animals’ muscle and heart cells, the researchers modified the Crispr-Cas9 gene scissors. “These gene scissors are highly efficient and specifically corrected the dystrophin gene,” says Prof. Wolfgang Wurst, developmental geneticist at TUM and the German Research Center for Environmental Health. It became then again possible to viably read the gene which had been unreadable because of the genetic defect, thus allowing for a successful protein biosynthesis. Now the shorter but stably formed dystrophin protein was able to improve muscle function. The animals treated were less susceptible to cardiac arrhythmia and had an increased life expectancy compared to animals with the disease that did not receive the therapy.
A permanent therapy
“Muscle and heart cells are long-lived cell structures. One half of all myocardial cells remain functional from birth throughout the entire lifecycle of a human being,” says Prof. Christian Kupatt, cardiologist at university hospital TUM Klinikum rechts der Isar. “The genome of a cell is used for protein biosynthesis as long as the cell is alive, and once a cell has been affected by the therapy, it remains corrected. So if we change the genome of a myocardial cell, the correction is a long-term success, in contrast to the results of previous methods.”
Therapeutic success with clinically relevant model
The gene sequence responsible for the dystrophin protein has already been successfully corrected in the past, however in mice and other animal models. “Our results are very promising, since for the first time, we have now been able to demonstrate therapeutic success in a clinically relevant large animal model,” says Prof. Maggie Walter, neurologist at the LMU university hospital. In terms of important biochemical, clinical and pathological changes, the pig model mirrors Duchenne muscular dystrophy in humans. “Since the disease proceeds faster in our pig model, we were able to verify the efficacy of the therapeutic approaches within a manageable period of time,” says Prof. Eckhard Wolf, LMU specialist in veterinary medicine.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Duchenne muscular dystrophy
- Team Ethan: Meet the 10-year-old Decatur boy serving as MDA's National Ambassadoron March 21, 2020 at 10:00 pm
Like many young children, summer camp, from water tubing to zip lining to water sliding, represents Ethan LyBrand’s favorite time of year. It is where the 10-year-old Decatur boy, despite his battle ...
- Capricor Therapeutics' (CAPR) CEO Linda Marban on Q4 2019 Results - Earnings Call Transcripton March 18, 2020 at 5:21 pm
All of us at Capricor are driven to achieve our goal of bringing our lead product candidate, CAP-1002 to patients for the treatment of Duchenne Muscular Dystrophy, and we are committed to expanding ...
- Catabasis Pharmaceuticals to Present During the Muscular Dystrophy Association Virtual Clinical Trials Sessionon March 18, 2020 at 5:18 pm
Catabasis Pharmaceuticals to Present During the Muscular Dystrophy Association Virtual Clinical Trials Session ...
- For People With Compromised Immune Systems, COVID-19 Is Seriouson March 18, 2020 at 1:25 pm
Michael Norton is one of those Americans. He's 32 years old, and he was born with Duchenne muscular dystrophy. That means he has to have a ventilator with him at all times to give him oxygen. To stay ...
- Capricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products Expansionon March 17, 2020 at 5:04 am
Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) ...
Go deeper with Google Headlines on:
Duchenne muscular dystrophy
Go deeper with Bing News on:
Gene correction therapy
- Stem Cell Therapy for Cystic Fibrosis: Current Status and Future Prospectson March 16, 2020 at 5:00 pm
In addition, the duration of gene expression has been ... An approach considering stem cell-based therapy of CF-injured lungs should achieve a permanent correction of the CF genetic defect.
- Scientists Use CRISPR Gene Editing Inside a Person’s Body: Why That's Significanton March 15, 2020 at 6:21 am
But whether in vivo or ex vivo, the pros of gene therapy using technologies like CRISPR probably outweigh the risks ... “The primary misconception of CRISPR gene editing is that it is a ‘plug-and-play ...
- Profiling haplotype specific CpG and CpH methylation within a schizophrenia GWAS locus on chromosome 14 in schizophrenia and healthy subjectson March 13, 2020 at 3:11 am
Schizophrenia is a common, highly heritable disorder characterized by positive, negative, and cognitive symptoms. Large genome-wide association studies (GWAS) of the Psychiatric Genomics Consortium ...
- They isolated themselves for 726 days to help daughter: Here's how they did iton March 12, 2020 at 5:16 pm
When the O'Neill family learned their daughter, Eliza, might qualify for gene therapy for her rare disease they decided to do anything to help. That meant isolating their family for nearly two years.
- Precision BioSciences Strengthens Board of Directors with Appointment of Geno Germanoon March 11, 2020 at 4:00 am
Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, announced today ...